Agios Pharmaceuticals Inc (Nasdaq:AGIO) Dips To New 52 Week Low

0
8
AGIO
AGIO

Agios Pharmaceuticals Inc (Nasdaq:AGIO)

December 6th, 2018
Agios Pharmaceuticals Inc went up $2.14 Thursday, up 3.96%, closing at $56.19. Despite ending the day higher, Agios Pharmaceuticals Inc hit a new 52 week low of $51.37, breaking the previous low of $53.42 from earlier this month. Agios Pharmaceuticals Inc swung 10.38% between low and high.

AGIO outperformed the rest of the Healthcare sector which went down 0.31% today.

Analysis results from 9 analysts indicates that Agios Pharmaceuticals Inc might increase significantly (75%), while Finbox has calculated (with medium uncertainty) a fair value price of $58.59.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending down. Real Estate saw the biggest increase of the day (2.67%), while Energy saw the biggest drop (1.77%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector falling 13%.

Communication Services saw the biggest turnaround from its 5-day performance of -0.23%, as it went up 1.04%. Energy and Materials saw turn arounds from their five day positive performance, Energy with a drop of 1.77%.

Sector Breakdown

  • Real Estate went up with a 2.67% change.
  • Communication Services went up with a 1.04% change.
  • Consumer Discretionary went up with a 0.61% change.
  • Information Technology went up with a 0.23% change.
  • Utilities went down with a -0.09% change.
  • Consumer Staples went down with a -0.10% change.
  • Healthcare went down with a -0.31% change.
  • Industrials went down with a -0.55% change.
  • Materials went down with a -1.38% change.
  • Financials went down with a -1.44% change.
  • Energy went down with a -1.77% change.

Agios Pharmaceuticals is based in Cambridge, United States of America. Agios Pharmaceuticals was founded in 2008.

Agios Pharmaceuticals Inc Info

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

All amounts in USD unless otherwise indicated
AGIO daily update

AGIO daily update
AGIO daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.